NeuCyte, Inc. is an innovative biotechnology company based in Mountain View, CA, specializing in CNS drug discovery. With their proprietary SynFire technology, they have developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling, focusing on genetically defined neurological diseases such as Alzheimer's disease, ALS, Epilepsy, and Fragile X Syndrome.
NeuCyte's mission is to accelerate and optimize CNS drug discovery by developing more predictive assays and platforms for phenotypic screening, addressing the high attrition rate of novel CNS drugs during clinical development. They utilize patient-derived and genetically engineered neural cell types to build unique cell-based assays for modeling neurological and neurodegenerative disorders, aiming to provide more biologically relevant models for studying functional links between targets and phenotypes.
Generated from the website